The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
How Will The Market Value Of The Omega 3 Prescription Drugs Market Change Between 2026 And 2030?
The omega 3 prescription drugs market has experienced robust expansion in recent years. Projections indicate it will grow from $1.75 billion in 2025 to $1.92 billion in 2026, at a compound annual growth rate (CAGR) of 9.9%. The historical growth can be attributed to the high prevalence of hypertriglyceridemia, increasing awareness of cardiovascular diseases, the rising geriatric population, the availability of prescription omega-3 drugs, and an increase in clinical research and trials.
The omega 3 prescription drugs market size is expected to undergo strong growth in the next few years, projected to reach $2.81 billion in 2030 at a compound annual growth rate (CAGR) of 10.0%. This expansion during the forecast period can be attributed to advancements in precision medicine, a rising demand for personalized therapies, the integration of digital health tools, market expansion in emerging regions, and innovation in omega-3 drug formulations. Major trends for the forecast period encompass the development of personalized omega-3 therapy, an increase in clinical trials for omega-3 formulations, growth in cardiovascular risk management solutions, broader accessibility of prescription omega-3 drugs, and enhanced nutraceutical-pharmaceutical integration.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8091&type=smp
Which Core Factors Are Supporting The Expansion Of The Omega 3 Prescription Drugs Market?
The growing incidence of cardiovascular diseases (CVDs) is anticipated to fuel the expansion of the omega-3 prescription drug market. Elevated levels of blood triglycerides, which are a fatty-like substance, are associated with a greater likelihood of cardiovascular disorders, and omega-3 supplements aid in regulating and lowering these triglyceride levels. Illustrating this trend, in August 2025, according to the National Institutes of Health, a US-based government agency, it is projected that between 2025 and 2050, cardiovascular prevalence will rise by 90%, mortality by 73%, and DALYs by 55%, with deaths increasing from 20.5 million to 35.6 million. Therefore, the rising cases of cardiovascular diseases (CVDs) are a key driver for the growth of the omega-3 prescription drug market.
What Are The Major Segment Categories Within The Omega 3 Prescription Drugs Market?
The omega 3 prescription drugs market covered in this report is segmented –
1) By Drug Type: Vascepa, Lovaza, Other Type
2) By Application Type: Hypertriglyceridemia, Other Application Type
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Subsegments:
1) By Vascepa: Pure EPA (Eicosapentaenoic Acid) Formulation, Indications For Cardiovascular Risk Reduction
2) By Lovaza: Combination Of EPA And DHA (Docosahexaenoic Acid), Indications For Hypertriglyceridemia Management
3) By Other Types: Epanova (Omega-3 Carboxylic Acids), Omega-3 Formulations In Clinical Trials, Other Prescription Omega-3 Products
What Trends Are Influencing The Future Of The Omega 3 Prescription Drugs Market?
Major companies operating in the omega-3 prescription drug market are focusing on product launches, such as capsules, designed to decrease the number of triglycerides produced by the body. Capsules are a pharmaceutical or dietary supplement dosage form, typically featuring a shell made of gelatin or a similar substance, which encloses a specific quantity of medication, nutrients, or other active ingredients in an easily ingestible and convenient format. For instance, in March 2023, Hikma Pharmaceuticals, an England-based multinational pharmaceutical company that manufactures generic and in-licensed pharmaceutical products, introduced Icosapent Ethyl Capsules, 0.5g, in the US. This product is indicated for reducing triglyceride levels in adults with severe hypertriglyceridemia, and it contains eicosatetraenoic acid (EPA), which is recognized for its triglyceride-lowering effects. This particular launch innovates the market by addressing severe hypertriglyceridemia, meeting the rising demand for pharmaceutical-grade omega-3 products, and aligning with the market’s focus on effective therapies for conditions like high triglyceride levels.
Who Are The Companies Shaping The Omega 3 Prescription Drugs Market Landscape?
Major companies operating in the omega 3 prescription drugs market are Pfizer Inc., Sanofi S.A., Amarin Corporation plc, GlaxoSmithKline plc, AstraZeneca plc, Merck & Co. Inc., Novartis AG, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim GmbH, BASF SE, DSM Nutritional Products, AbbVie Inc., Eli Lilly and Company, Bayer AG, Shire Pharmaceuticals, Mylan NV, Teva Pharmaceutical Industries Ltd., Horizon Therapeutics, Kyowa Kirin Co. Ltd., Sumitomo Pharma Co. Ltd.
Access The Complete Omega 3 Prescription Drugs Market Report:
https://www.thebusinessresearchcompany.com/report/omega-3-prescription-drugs-global-market-report
Which Region Contributes The Most To The Omega 3 Prescription Drugs Market?
North America was the largest region in the omega 3 prescription drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the omega 3 prescription drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Omega 3 Prescription Drugs Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=8091&type=smp
Browse Through More Reports Similar to the Global Omega 3 Prescription Drugs Market 2026, By The Business Research Company
Omega 3 Prescription Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/omega-3-prescription-drugs-global-market-report
Omega 3 Market Report 2026
https://www.thebusinessresearchcompany.com/report/omega-3-global-market-report
Osteoporosis Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/osteoporosis-drugs-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model